SCHEMBL162679

SCHEMBL162679

CS(=O)(=O)N1CCC(c2ncc(-c3ccc(NC(=O)Nc4ccccc4F)cc3)s2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 6/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
TSHR P16473 1/20 0.51
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CYP1A2 P05177 1/20 0.42
CA9 Q16790 1/20 0.42
KDR P35968 3/20 0.42
TEK Q02763 2/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
HTT P42858 2/20 0.42
POLB P06746 1/20 0.42
EPHB4 P54760 1/20 0.41
AURKB Q96GD4 1/20 0.41
PKM P14618 1/20 0.41
NFKB1 P19838 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL161432 0.90 DGAT1 (0.55) DGAT1SMN1; SMN2MEN1KMT2ACA12
SCHEMBL164736 0.90 DGAT1 (0.52) DGAT1SMN1; SMN2TSHRMEN1KMT2A
SCHEMBL160037 0.90 DGAT1 (0.54) DGAT1SMN1; SMN2MEN1KMT2AKDR
SCHEMBL163448 0.90 DGAT1 (0.53) DGAT1SMN1; SMN2TSHRMEN1KMT2A
SCHEMBL160969 0.86 NPY5R (0.45) DGAT1MEN1KMT2AKDREPHX2
SCHEMBL161576 0.85 DGAT1 (0.55) DGAT1SMN1; SMN2KMT2AKDRTEK
SCHEMBL162213 0.85 DGAT1 (0.55) DGAT1SMN1; SMN2MEN1KMT2AKDR
SCHEMBL159317 0.84 DGAT1 (0.56) DGAT1SMN1; SMN2MEN1KMT2AKDR
SCHEMBL161991 0.83 DGAT1 (0.51) DGAT1SMN1; SMN2NPC1RAB9APKM
Hydrochloric Acid SCHEMBL160909 0.83 DGAT1 (0.57) DGAT1SMN1; SMN2MEN1KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP claimed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US claimed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO claimed
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP disclosed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US disclosed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS DGAT1, DGAT2, SOAT1 DGAT1 1/4885SMN1; SMN2 2105/4885TSHR 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.